INSM

Insmed Incorporated Common Stock

$97.79

Current Price

All

AI analysis

Read what the AI thinks of Insmed Incorporated Common Stock in the app.

Analyses are generated by AI from public data and are not investment advice.

Get the app

Key figures

Dividend per share

—

Yield

—

EPS

-$4.10

P/E

—

Data as of Oct 8

Why it matters for the long term

Over 10-20 years, what drives a share up is the growth of its profits (EPS) + reinvested dividends. The P/E tells you whether you are paying a lot or a little for that growth. In short: rising EPS + reasonable P/E + growing dividend = good long-term candidate.

Upcoming events

Quarterly earnings

Expected EPS: -$0.38

Oct 28

Posts

No posts about INSM yet.

About Insmed Incorporated Common Stock

Insmed is a biotechnology company that develops drugs for rare lung diseases and other serious conditions. Its main product, Arikayce, treats a stubborn lung infection called MAC lung disease. The company earns money by selling its drugs to patients through hospitals and specialty pharmacies, and it is spending heavily to bring new medicines to market.